| Jun 2, 2026 | finance.yahoo.com | Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism |
| May 18, 2026 | finance.yahoo.com | Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market |
| May 13, 2026 | finance.yahoo.com | Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy |
| Apr 30, 2026 | finance.yahoo.com | Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months |
| Mar 30, 2026 | finance.yahoo.com | Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 |
| Mar 26, 2026 | finance.yahoo.com | Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient |
| Mar 17, 2026 | finance.yahoo.com | Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance |
| Mar 5, 2026 | finance.yahoo.com | CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data |
| Mar 4, 2026 | finance.yahoo.com | Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds |
| Mar 4, 2026 | finance.yahoo.com | Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study |
| Feb 17, 2026 | finance.yahoo.com | Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson |
| Feb 9, 2026 | finance.yahoo.com | Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy |
| Feb 5, 2026 | finance.yahoo.com | Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson |
| Jan 20, 2026 | finance.yahoo.com | Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson |
| Dec 26, 2025 | finance.yahoo.com | Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction |
| Dec 26, 2025 | finance.yahoo.com | Top Midday Stories: Nvidia-Groq Licensing Deal; Target Attracts Growing Interest From Toms Capital |
| Dec 26, 2025 | finance.yahoo.com | Sector Update: Health Care Stocks Edge Higher Late Afternoon |
| Dec 26, 2025 | finance.yahoo.com | Sector Update: Health Care Stocks Lower in Friday Afternoon Trading |
| Dec 23, 2025 | finance.yahoo.com | Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change |
| Dec 16, 2025 | finance.yahoo.com | Can-Fite Provides Update on Clinical and Financial Status |
| Nov 26, 2025 | finance.yahoo.com | Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference |
| Nov 24, 2025 | finance.yahoo.com | Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference |
| Nov 20, 2025 | finance.yahoo.com | Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil |
| Nov 18, 2025 | finance.yahoo.com | Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson |
| Nov 18, 2025 | finance.yahoo.com | Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as Investors Await Clues on Fed's Interest Rate Cut |
| Sep 15, 2025 | finance.yahoo.com | Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson |
| Aug 28, 2025 | finance.yahoo.com | Can-Fite Reports H1 2025 Financial Results and Clinical Update |
| Jul 30, 2025 | finance.yahoo.com | Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone |
| Jul 28, 2025 | finance.yahoo.com | Can-Fite Announces Up To $15.0 Million Public Offering |
| Jul 28, 2025 | finance.yahoo.com | Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia |
| Jun 16, 2025 | finance.yahoo.com | Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston |
| May 5, 2025 | finance.yahoo.com | Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis |
| Apr 17, 2025 | finance.yahoo.com | Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients |
| Apr 14, 2025 | finance.yahoo.com | Can-Fite Reports 2024 Financial Results and Clinical Update |
| Apr 14, 2025 | finance.yahoo.com | Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships |
| Apr 14, 2025 | finance.yahoo.com | Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares |
| Mar 28, 2025 | finance.yahoo.com | bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV |
| Mar 24, 2025 | finance.yahoo.com | Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol |
| Mar 20, 2025 | finance.yahoo.com | Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market |
| Mar 19, 2025 | finance.yahoo.com | Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson |
| Mar 18, 2025 | finance.yahoo.com | Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient |
| Mar 3, 2025 | finance.yahoo.com | Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits |
| Feb 18, 2025 | finance.yahoo.com | Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson |
| Feb 10, 2025 | finance.yahoo.com | Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25 |
| Feb 5, 2025 | finance.yahoo.com | Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025 |
| Jan 28, 2025 | www.pharmaceutical-technology.com | Can-Fite BioPharma secures US patent for Namodenoson |
| Jan 27, 2025 | finance.yahoo.com | US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug |
| Jan 9, 2025 | finance.yahoo.com | CanFite Biopharma (CANF) Upgraded to Strong Buy: Here's What You Should Know |
| Dec 30, 2024 | finance.yahoo.com | Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson |
| Dec 9, 2024 | finance.yahoo.com | Bears are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now |
| Dec 4, 2024 | finance.yahoo.com | 8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug |
| Nov 22, 2024 | finance.yahoo.com | 60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV |
| Nov 11, 2024 | finance.yahoo.com | Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial |
| Nov 5, 2024 | finance.yahoo.com | Can-Fite BioPharma Secures Australian Patent for Obesity Drug |
| Nov 4, 2024 | finance.yahoo.com | Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia |
| Oct 18, 2024 | finance.yahoo.com | Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson |
| Oct 9, 2024 | finance.yahoo.com | FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer |
| Oct 7, 2024 | finance.yahoo.com | Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29 |
| Sep 24, 2024 | finance.yahoo.com | Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis |
| Sep 16, 2024 | finance.yahoo.com | Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health |
| Aug 30, 2024 | finance.yahoo.com | Is Can-Fite BioPharma Ltd. (CANF) The Best Rated Penny Stock To Buy According to Analysts? |
| Aug 29, 2024 | finance.yahoo.com | Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies |
| Aug 9, 2024 | finance.yahoo.com | OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV |
| Aug 8, 2024 | finance.yahoo.com | Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds |
| Jul 29, 2024 | finance.yahoo.com | Can-Fite Provides Namodenoson Patent Update |
| Jul 17, 2024 | finance.yahoo.com | Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8 |
| Jul 11, 2024 | finance.yahoo.com | Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer |
| Jul 1, 2024 | finance.yahoo.com | Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson |
| Jun 28, 2024 | www.businesswire.com | Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix |
| Jun 24, 2024 | www.businesswire.com | Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver |
| Jun 10, 2024 | www.businesswire.com | Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study |
| Jun 5, 2024 | www.businesswire.com | Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study |
| May 29, 2024 | www.businesswire.com | Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases |
| May 27, 2024 | www.businesswire.com | Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024 |
| May 23, 2024 | www.businesswire.com | Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6 |
| May 13, 2024 | www.businesswire.com | Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study |
| May 10, 2024 | www.clinicaltrialsarena.com | Can-Fite receives FDA IND clearance for Phase IIb MASH treatment trial |
| May 10, 2024 | finance.yahoo.com | Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV |
| May 9, 2024 | www.businesswire.com | Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study |
| May 6, 2024 | www.businesswire.com | Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602 |
| Apr 29, 2024 | finance.yahoo.com | Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV |
| Apr 25, 2024 | www.businesswire.com | Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal |
| Apr 15, 2024 | www.businesswire.com | Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH |
| Apr 3, 2024 | www.businesswire.com | Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients |
| Apr 2, 2024 | www.businesswire.com | Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients |
| Apr 1, 2024 | finance.yahoo.com | Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV |
| Mar 28, 2024 | www.businesswire.com | Can-Fite Reports 2023 Financial Results and Clinical Update |
| Mar 27, 2024 | www.businesswire.com | Can-Fite Reports 2023 Financial Results and Clinical Update |
| Mar 11, 2024 | www.businesswire.com | Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference |
| Feb 28, 2024 | www.businesswire.com | Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada |
| Jan 30, 2024 | www.businesswire.com | Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication |
| Jan 29, 2024 | www.businesswire.com | Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study |
| Dec 20, 2023 | www.businesswire.com | The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies |
| Dec 18, 2023 | www.businesswire.com | Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan |
| Dec 4, 2023 | www.businesswire.com | Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development |
| Nov 30, 2023 | www.businesswire.com | Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update |
| Nov 22, 2023 | finance.yahoo.com | Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson |
| Nov 21, 2023 | finance.yahoo.com | Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds |
| Nov 21, 2023 | www.businesswire.com | Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson |
| Nov 1, 2023 | www.businesswire.com | Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track |